Multinationals’ China Trial Strategies Shift As Industry Adapts
This article was originally published in The Pink Sheet Daily
2013 marked a new low for clinical trial approvals in China. A compliance crackdown that has brought caution to multinational firms in particular has added to fast-paced changes evident in the industry, says a clinical research insider with years of experience at multinational drug makers in China.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.